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Background: A single nucleotide polymorphism (SNP) within MIR137, the host gene
for miR-137, has been identified repeatedly as a risk factor for schizophrenia. Previous
genetic pathway analyses suggest that potential targets of this microRNA (miRNA)
are also highly enriched in schizophrenia-relevant biological pathways, including those
involved in nervous system development and function.
Methods: In this study, we evaluated the schizophrenia risk of miR-137 target genes
within these pathways. Gene set enrichment analysis of pathway-specific miR-137
targets was performed using the stage 1 (21,856 subjects) schizophrenia genome
wide association study data from the Psychiatric Genomics Consortium and a small
independent replication cohort (244 subjects) from the Mind Clinical Imaging Consortium
and Northwestern University.
Results: Gene sets of potential miR-137 targets were enriched with variants associated
with schizophrenia risk, including target sets involved in axonal guidance signaling,
Ephrin receptor signaling, long-term potentiation, PKA signaling, and Sertoli cell junction
signaling. The schizophrenia-risk association of SNPs in PKA signaling targets was
replicated in the second independent cohort.
Conclusions: These results suggest that these biological pathways may be involved
in the mechanisms by which this MIR137 variant enhances schizophrenia risk. SNPs
in targets and the miRNA host gene may collectively lead to dysregulation of target
expression and aberrant functioning of such implicated pathways. Pathway-guided gene
set enrichment analyses should be useful in evaluating the impact of other miRNAs and
target genes in different diseases.
Keywords: schizophrenia, miR-137, microRNA, gene set enrichment analysis (GSEA), pathway analysis, PKA
signaling
Wright et al. Schizophrenia risk of miR-137 targets
Introduction
MicroRNAs (miRNAs) are a class of noncoding RNAs involved
in posttranscriptional gene expression regulation by binding to
complementary sequences within target mRNAs (Bartel, 2009).
miRNAs play a role in a variety of cellular processes and dis-
eases (Henrion-Caude et al., 2012), including psychiatric disor-
ders (Mellios and Sur, 2012). Several lines of evidence support a
role of miR-137 in schizophrenia, a severe mental illness charac-
terized by symptoms of delusions, hallucinations, and diminished
sociability. Not only was the strongest associated SNP identified
in the first large schizophrenia genome wide association study
(GWAS) located in the host gene of miR-137 (Ripke et al., 2011)
but also the other top four polymorphisms mapped to validated
target genes of this miRNA (Kwon et al., 2013). This miRNA is
involved in several steps in neuronal development, from regu-
lation of neuronal proliferation and differentiation (Silber et al.,
2008; Smrt et al., 2010; Szulwach et al., 2010; Sun et al., 2011) to
dendritic arborization (Smrt et al., 2010), suggesting that the risk
allele may impact these processes. Additionally, imaging genet-
ics studies have found distinct alterations associated with the
MIR137 risk variant in subjects with schizophrenia. One recent
functional magnetic resonance imaging (fMRI) study identified
alterations in brain activity patterns during a sentence comple-
tion task within the amygdala and pre and postcentral gyrus only
in risk allele carrier subjects that were also at risk for schizophre-
nia development (Whalley et al., 2012). Structural imaging analy-
ses also identified patient-specific alterations in risk allele carriers
such as reduced whole brain functional anisotropy, reduced left
hippocampal volume and enlarged right and left lateral ventricle
volume (Lett et al., 2013). In contrast, no volumetric alterations
were found in protective-allele carrying patients or healthy risk
allele carriers (Li and Su, 2013). The disease-specific risk allele
associations found in these studies suggest that, in agreement
with the evidence of polygenic risk in schizophrenia (Purcell
et al., 2009), other genetic factors besides the MIR137 SNP may
underlie disease-specific abnormalities in brain structure and
function. Polymorphisms withinmultiplemiR-137 targetsmay in
part increase genetic risk by potentially enhancing dysregulation
by this miRNA. Variants within or adjacent to miRNA recogni-
tion sites in 3′ UTRs can alter binding and binding availability
of miRNAs to target mRNAs, leading to altered gene expression
and phenotypic or disease states (Abelson, 2005; Wang et al.,
2008) Therefore, collective polymorphisms within miR-137 tar-
get genes in schizophrenia-relevant pathways may disrupt regu-
lation by this miRNA, and/or lead to a general disruption of the
pathways in the patients.
Initial bioinformatics analyses of the function of putative and
validated targets suggest that miR-137 target genes are involved
in many schizophrenia relevant pathways, including axonal guid-
ance signaling, Ephrin receptor signaling, synaptic long term
potentiation (LTP), and protein kinase A (PKA) signaling, among
others (Wright et al., 2013). Besides LTP, little is known about
the role of these miR-137 regulated pathways in schizophrenia.
Preliminary SNP by SNP association analyses performed by the
PGC found significant enrichment of risk associated SNPs within
a subset of predictedmiR-137 target genes (Ripke et al., 2011) and
this was replicated with a larger set of predicted targets, using
a joint gene set enrichment analysis (Ripke et al., 2013, 2014).
However, no studies to date have examined the collective risk of
miR-137 target SNPs across biological pathways.
The goals of this study were to assess the schizophrenia-risk
of both experimentally validated and high confidence predicted
miR-137 targets, and to evaluate for the first time the risk associa-
tion of these targets in a pathway-specific manner. These analyses
were performed using meta gene set enrichment analyses of spe-
cific target gene sets (Segrè et al., 2010). Gene set enrichment
analysis (GSEA) is particularly useful in the case of polygenic dis-
eases such as schizophrenia (Purcell et al., 2009) as it allows for
examination of the collective effect of multiple polymorphisms.
Furthermore, analysis of gene sets in a pathway specific frame-
work can also increase the power to detect collective moderate
risk associations and can allows for evaluation of more biolog-
ically relevant and interpretable genetic effects particularly with
genetically complex disorders (Juraeva et al., 2014). In this study
we identified pathway-specificmiR-137 target gene sets, and eval-
uated their risk association both within the PGC Stage 1 GWAS
data (Ripke et al., 2011) and within a smaller independent dataset
including subjects from the Mind Clinical Imaging Consortium
(MCIC) (Gollub et al., 2013) and Northwestern University (NU)
(Wang et al., 2013). The evaluation of pathway-specific gene sets
in this manner allows for an estimation of schizophrenia-risk due
to miR-137 dysregulation.
Materials and Methods
miR-137 Regulated Gene Curation and Prediction
Experimentally validated targets and 2 indirectly regulated genes
(MAPK1 and MAPK3) were curated (36 in total) from the lit-
erature as described previously for the identification of 26 regu-
lated genes inWright et al. (2013). AdditionallyHTT (Kozlowska
et al., 2013), TBX3 (Jiang et al., 2013), GLIPR1 (RTVP-1) (Ariel
Bier et al., 2013), CLDN11, GABRA1, NRXN1, NEFL, ZNF365,
NECAP1, and RAPGEF5 (Boudreau et al., 2014) were included as
validation experiments were published since (Wright et al., 2013).
Targets were predicted using TargetScan version 6.2, released
June 2012 (Lewis et al., 2005). Target prediction databases are
known to include false positive miRNA-mRNA interactions and
to exclude true interactions (Zheng et al., 2013). TargetScan offers
two scoring systems to improve confidence in target-miRNA pre-
diction: the probability of conserved targeting (Pct) score and the
context score. The Pct score (with a range from 0 to 1, with 1 indi-
cating highest) is derived by evaluating the conservation of the
interaction site sequence across species (Friedman et al., 2009).
Highly conserved binding sites are more likely to be function-
ally relevant and effective in inducing subsequent mRNA repres-
sion (Nielsen et al., 2007; Friedman et al., 2009). However, target
interactions that may have evolved later in primates and humans
are less likely to be conserved (Glazov et al., 2008; Friedman
et al., 2009) and may be more relevant to higher order cogni-
tion and complex behavior phenotypes, such as those affected
in schizophrenia. Thus some human-specific or primate-specific
targets may be lost based on conservation score (Farh et al., 2005;
Grimson et al., 2007). The context score provides confidence for
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the less conserved targets and improved confidence for conserved
targets. This score (with a range from 0 to −1, with −1 indicat-
ing more probable binding) is based on evaluation of site effi-
cacy including seed site interaction type, nearby nucleotides, site
location, and seed site interaction stability among other criteria
(Grimson et al., 2007; Garcia et al., 2011). Therefore, site con-
servation and site efficacy were both used, either separately or
combined, to better capture the potential impact of miR-137 on
biological pathways.
The four predicted miR-137 target gene lists, each including
validated targets, that were curated for further analysis (Supple-
mental Table 1) included: (a) the full target list as predicted by
TargetScan (full target list), (b) targets with Pct scores greater
than or equal to 0.9 (conserved target list), (c) targets with the
best 50% of context scores (context target list), and (d) the high
Pct and low context scoring targets (intersection target list). The
Pct score cutoff of 0.9 was based on previous work of Ripke et al.
(2011). The context score, with an equal percentage of predicted
targets as that chosen for the Pct score, was −0.12. Finally, the
intersection of targets with Pct scores greater than or equal to 0.9
and with context scores below −0.12 was used as a higher confi-
dence predicted list that represents more plausible conserved tar-
gets. The full lists of these gene sets are shown in Supplementary
Table 2 (see yellow highlighted cells).
Pathway Selection Criterion
Selection of gene sets was based on prior pathway analysis of
the full list of TargetScan predicted targets and validated targets
using Ingenuity Pathway Analysis (IPA) as described previously
in Wright et al. (2013). From this analysis it was determined
that several possibly schizophrenia-relevant pathways were sig-
nificantly enriched with potential miR-137 target genes. The top
10 enriched pathways for potential targets, listed in Table 1 were
selected for pathway-specific gene set enrichment analyses. Since
IPA now allows for multiple testing correction of pathway enrich-
ment, this was reassessed with the Benjamini-Hochberg multiple
testing correction and all pathways were still found to be among
the top 11 significantly enriched pathways (corrected p < 0.01)
(Supplemental Table 3). Gene sets of miR-137 target genes of var-
ied prediction confidence were created for each pathway using
the target gene lists described above. See Supplemental Table 2
for the full lists of genes within each tested gene set.
Meta Gene Set Enrichment of Variant Analysis
(MAGENTA)
The MAGENTA software program (Segrè et al., 2010) evaluates
enrichment of modest associations with a disease or trait within
gene sets using GWAS disease association p-values and odds
ratios. MAGENTA includes SNPs within a region from 110 kb
upstream to 40 kb downstream of each gene’s transcript bound-
aries. The SNP with the smallest disease association p-value
within this region is determined for later analysis as the “gene’s
best” association p-value. Such a procedure helps overcome the
“watering-down” effects that occur when analyzing the average
SNP p-value across a gene, where unassociated SNPs can depre-
ciate gene association. The following confounds are addressed by
correcting the smallest gene SNP p-values with step-wise linear
regression: gene size, number of SNPs per gene kb, number of
independent SNPs per gene kb, number of recombination spots
per gene kb, linkage disequilibrium units per gene kb, and genetic
distance per gene kb (Segrè et al., 2010).
MAGENTA uses corrected best gene disease association p-
values to evaluate the enrichment of each gene set with, in this
case, genes containing a schizophrenia-associated variant. Gene
sets are compared to 10,000 random gene sets of identical size.
The gene set p-value is calculated as the fraction of random
gene sets with a sum rank p-value equal or smaller than that of
the tested gene set. Gene sets with a one-tailed Mann-Whitney
like rank-sum based false discovery rate (FDR) (Sabatti et al.,
2003) q-value of <0.05 were considered significantly enriched
with associated SNPs based on the FDR gene score enrichment
cutoff of 75%. This cutoff is based on the fraction of p-values
TABLE 1 | Gene sets of potential hsa-miR-137 targets evaluated in MAGENTA.
Evaluated gene set in MAGENTA Full list Conserved list Context list Intersection list Validated list
Gene Set size 1154 560 597 311 36
PATHWAY SPECIFIC GENE SETS
Sertoli cell junction signaling 27 16 15 11 4
Mechanisms of cancer 40 25 22 17 8
Hepatocyte growth factor (HGF) signaling 18 13 12 9 6
Ephrin receptor signaling 25 16 12 10 3a
Agrin interactions at neuromuscular junctions 14 9 8 6 3a
Gonadotropin Releasing Hormone (GNRH) signaling 20 12 6 6 3a
Cardiac –B adrenergic signaling 20 10 4 2 1
Synaptic long term potentiation (LTP) 19 11 7 4 3
Protein kinase A (PKA) signaling 42 26 18 10 4
Axonal guidance signaling 42 20 18 13 3a
This table shows the number of potential miR-137 target genes evaluated in each gene list and the number of genes in each pathway-specific gene set derived from each target gene
list. MAGENTA, Meta Gene Set Enrichment of Variant Analysis.
a Identical gene sets.
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lower than 75% of all gene p-values and is suggested for polygenic
diseases such as is proposed for schizophrenia (Purcell et al.,
2009) where association values may be more modest (Segrè et al.,
2010).
Database and GWAS Information
To determine whether the gene sets in Table 1 are enriched
in schizophrenia risk variants, p-values from two independent
GWAS were evaluated. The first p-values were derived from the
stage 1 GWAS study reported in Ripke et al. (2011), the GWAS
in which the schizophrenia risk association was discovered for
the miR-137 host gene SNP, rs1625579. This analysis included
21,856 subjects (9394 cases and 12,462 controls) of European
ancestry from the Psychiatric GWAS Consortium (PGC) (Sup-
plemental Table 4). Genotyping was performed using Affymetrix
and Illumina Chips across samples. Quality control was con-
ducted as described in Ripke et al. (2011). The unadjusted p-
values and odds ratios for the 1.2 million SNPs evaluated in
this GWAS are available on the PGC website, http://www.med.
unc.edu/pgc/downloads. GWAS p-values and odds ratios were
loaded into MAGENTA (Segrè et al., 2010) with one gene set file
including all gene sets in Table 1 to allow cross-comparison of
gene sets, as permutation differences can cause slightly different
results.
To evaluate if the PGC MAGENTA results were replica-
ble, subjects were analyzed from the Mind Clinical Imaging
Consortium (MCIC) (Gollub et al., 2013) and Northwestern
University (NU) (Wang et al., 2013) (Supplemental Table 4).
All participants provided written informed consent, and the
Institutional Review Board at each site approved this project.
Genotyping was conducted at the Mind Research Network Neu-
rogenetics Core lab using Illumina HumanOmni-Quad 1M and
5M BeadChips respectively. Only Caucasian subjects were used
to avoid population-specific effects. Caucasians were identified
using the Enhancing Neuroimaging Genetics through Meta-
Analysis (ENIGMA) multi-dimensional scaling (MDS) proto-
col within the imputation protocol (http://enigma.ini.usc.edu/
protocols/genetics-protocols/). Genotype data from each dataset
was merged using PLINK after updating the MCIC SNP loca-
tions to match that of the more recent NU data. Quality con-
trol was performed before and after merging similarly to that
of Ripke et al. (2011), using PLINK with the following thresh-
olds: Hardy Weinberg equilibrium P < 10−6, minor allele fre-
quency < 0.05, missing rate per SNP < 0.02, missing rate per
individual < 0.02. Relatedness and population stratification test-
ing was performed using PLINK. Outliers were identified and
removed as well as one individual per pair that appeared to be
related, according to pi-hat values of 0.05 or greater per pair of
individuals. After all quality control and pruning, a total of 244
individuals remained (103 cases and 141 controls) and 539,288
SNPs.
A GWAS study using logistic regression covarying for chip
type was performed on themergedMCIC andNU genotypic data
with a genomic inflation factor of 1.00737. The p-values obtained
were evaluated using MAGENTA for the previously significantly
enriched gene sets found in the PGC data.
Results
Magenta Analyses of miR-137 Predicted and
Validated Target Lists
Gene sets for each of the target lists of different prediction con-
fidences were first evaluated for enrichment of schizophrenia
risk SNPs (Table 2). The higher confidence predicted lists, i.e.,
the conserved, context, and intersection, were all significantly
enriched with schizophrenia-associated variants. As shown in
Figure 1, the IPA network derived from the 77 intersection tar-
gets that were associated with neurological disease contains many
nervous system expressed genes including some schizophrenia-
associated genes that interact with one another. The validated tar-
get list was not significantly enriched with variants, likely due to
the small size of this set. The full list of putative targets, although
trending, was not enriched either, possibly due to a higher inclu-
sion of false positive miRNA-target interactions. This suggests
that the high confidence predicted miR-137 target genes overall
contain SNPs that are associated with schizophrenia.
MAGENTA Analyses of miR-137 Target Pathway
Gene Sets
The schizophrenia-risk of miR-137 validated and predicted tar-
gets was assessed after targets were classified within canonical
pathways according to IPA. Meta gene set enrichment of vari-
ant association analysis using MAGENTA software (Segrè et al.,
2010) revealed several pathway relevant gene sets of miR-137 tar-
gets significantly enriched with schizophrenia-associated variants
(Table 3). For a list of the variants identified for each significant
gene set see Supplementary Table 5. Ephrin receptor signaling,
axonal guidance signaling, and Sertoli cell junction signaling gene
sets were significantly enriched with schizophrenia-associated
variants from four out of five gene lists (Table 3). The enrich-
ment found for nearly all gene sets specific to these pathways
using higher confidence target lists, strongly suggests that these
pathways are indeed enriched with miR-137 target genes asso-
ciated with schizophrenia risk. Additionally, synaptic LTP gene
sets from the intersection and validated gene lists, and PKA sig-
naling gene sets from the full and validated target lists, were
enriched in risk genes. The mechanism of cancer gene set was
TABLE 2 | Curated hsa-miR-137 target gene lists show enrichment for
association with schizophrenia.
Gene set MAGENTA Nominal GSEA p-value FDR q-value
Gene set size with 75% cutoff with 75% cutoff
Full List 1061 1.32E-02 5.11E-02
Conserved List 548 1.50E-03 1.96E-02
Context List 585 3.90E-03 1.89E-02
Intersection List 329 2.50E-03 1.90E-02
Validated List 36 9.08E-02 9.75-02
This table shows the results of the target gene lists including the number of genes after
conversion to ENTREZ IDs, the gene set enrichment analysis (GSEA) p-value before false
discovery rate (FDR) correction,and the FDR q-value used to determine significance at a
threshold of q < 0.05. Significant gene lists are shown in bold. MAGENTA, Meta Gene
Set Enrichment of Variant Analysis.
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FIGURE 1 | miR-137 Intersection Target Network of Neurological
Disease. Top network derived from a core analysis using Ingenuity Pathway
Analysis with the 77 genes of the intersection target list that are associated
with Neurological Disease. Predicted targets are indicated in yellow, targets
associated with schizophrenia are outlined in light blue and validated targets
are indicated in orange.
also significantly enriched, but only from the validated target list.
Overall, analysis of pathway specific gene sets derived from the
multiple potential target lists provided higher confidence for the
potential impact of this miRNA within these pathways.
MCIC and NU Replication Cohort Results
MAGENTA analysis of a replication cohort using the MCIC
(Gollub et al., 2013) and NU (Wang et al., 2013) dataset GWAS
association p-values revealed one significantly enriched gene set.
The PKA signaling gene set from the validated target list, includ-
ing TCF4 and PTGS2, as well asMAPK1,MAPK3 (experimentally
validated indirectly regulated genes), was significantly enriched
with a nominal GSEA p-value of 0.003 and an FDR q-value of
0.014. Supplemental Table 6 shows the top SNPs from this anal-
ysis. As shown in Figure 2, the canonical PKA signaling pathway
from IPA is enriched with predicted and validated miR-137 regu-
lated genes, suggesting that this pathway may be involved in the
mechanism of the miRNA in schizophrenia.
Discussion
Current research about the first discovered MIR137 host gene
SNP in schizophrenia, rs1625579, suggests that this variant
impacts some endophenotypic measures in patients and controls
in a different manner (Whalley et al., 2012; Lett et al., 2013). In
addition to the SNPs in this same locus discovered in the Ripke
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TABLE 3 | Significantly enriched hsa-miR-137 pathway-specific gene sets.
Gene set Gene list MAGENTA gene Set size Nominal GSEA p-value with 75% cutoff FDR q-value with 75% cutoff
Axonal guidance signaling Conserved 19 8.00E-04 4.85E-03
Context 18 5.60E-03 1.99E-02
Intersection 13 5.80E-03 2.13E-02
Full 40 1.14E-02 2.82E-02
Ephrin receptor signaling Conserved 16 4.10E-05 7.00E-04
Full 25 1.00E-03 8.43E-03
Context 12 2.20E-03 1.18E-02
Intersection 10 3.80E-03 1.36E-02
Synaptic LTP Validated 3 1.69E-02 1.89E-02
Conserved 13 2.19E-02 3.23E-02
Mechanisms of Cancer Validated 8 2.59E-02 2.75E-02
PKA signaling Full 46 1.03E-02 2.97E-02
Validated 4 4.73E-02 4.18E-02
Sertoli cell junction signaling Intersection 11 7.40E-03 1.84E-02
Conserved 16 6.40E-03 1.84E-02
Context 15 1.48E-02 2.75E-02
Validated 4 5.24E-02 4.88E-02
This table shows the results for the pathway-specific gene sets of Table 1 including the number of genes after conversion to ENTREZ IDs, the gene set enrichment analysis (GSEA)
p-value before false discovery rate (FDR) correction, and the FDR q-value used to determine significance at a threshold of q < 0.05. All gene sets pass the significance threshold.
MAGENTA, Meta Gene Set Enrichment of Variant Analysis.
et al. (2013, 2014), variable number tandom repeats (VNTRs) and
rare variants (Duan et al., 2014; Strazisar et al., 2014; Warburton
et al., 2014) within the locus may also influence schizophrenia
risk. miR-137 has been shown to alter the expression of genes
involved in neuronal differentiation (Hill et al., 2014) and to
downregulate genes associated with schizophrenia risk (Collins
et al., 2014). Therefore, it is likely that the interaction of these
schizophrenia-associated MIR137 variants with additional vari-
ants within miR-137 regulated genes present in patients may
increase both dysregulation by this miRNA and schizophrenia
risk. These additional variants may disrupt targeting efficiency
or lead to general disruption of pathway-specific genes, col-
lectively altering biological processes required for proper brain
functioning.
We have previously shown that miR-137 target genes fall
within certain biological pathwaysmore frequently than expected
by chance (Wright et al., 2013). Data presented in this study
clearly indicates that the genes in these miR-137 regulated path-
ways are also enriched with schizophrenia risk variants, suggest-
ing a potential mechanism for the association of the MIR137
risk variant. These pathways include Ephrin receptor signaling
targets, axonal guidance signaling targets, synaptic LTP targets,
Sertoli cell junction signaling targets, and PKA signaling targets.
As described below, there is supporting evidence for how each of
these may indeed enhance the risk of schizophrenia or impact the
etiology of the disorder.
Ephrin receptor signaling is closely linked to axonal guid-
ance and synaptic LTP, particularly NMDA dependent plasticity
(Filosa et al., 2009). Interactions of the Ephrin receptors across
adjacent neurons or glial cells and neurons help to guide axonal
repulsion (Xu and Henkemeyer, 2012), dendritic spine stability,
synaptogenesis (Lin and Koleske, 2010), and control synapse glu-
tamate concentrations (Filosa et al., 2009), all of which impact
LTP. Schizophrenia imaging genetics studies have found asso-
ciations between axonal guidance signaling genes and predic-
tion of fMRI measures of dorsolateral prefrontal cortex (DLPFC)
inefficiency during a working memory task (Walton et al.,
2013). A link between altered LTP and schizophrenia was shown
more directly in a transcranial direct current stimulation (tDCS)
study, which found altered LTP-like plasticity in patients (Hasan
et al., 2013). Additionally, schizophrenia animal models using
NMDAR antagonists, have shown effects on both LTP and behav-
ior measures demonstrating similar alterations to the cognitive,
negative, and positive symptoms found in humans (Wiescholleck
and Manahan-Vaughan, 2013). This suggests that Ephrin recep-
tor signaling and axonal guidance alterations leading to changes
in NMDA driven synaptic LTP alterations could lead to all three
spectra of symptoms associated with the disorder.
The enrichment of Sertoli cell junction signaling gene sets is
compelling as increased risk of schizophrenia is associated with
increased paternal and grandpaternal age (Frans et al., 2011).
Sertoli cells create the supportive niche for the spermatogo-
nial stem cells and create the blood-testis barrier (Kaur et al.,
2014). It is suggested that reduced Sertoli cell population with
age may reduce both germ cell production and quality (Paul and
Robaire, 2013). Perhaps alterations in Sertoli cell function via
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dysregulation by this miRNA could also reduce germ cell quality
of patient fathers and grandfathers.
Finally, the miR-137 validated target PKA signaling gene set
(MAPK1, MAPK3, TCF4, and PTGS2) is of particular interest
given that enrichment of schizophrenia-risk associated variants
within these targets was replicated in an independent cohort.
PKA is involved in the biological pathways of two neurotransmit-
ters implicated schizophrenia, as it not only modulates glutamate
signaling but also responds to dopamine signaling (Sarantis et al.,
2009). PKA signaling also appears to play a critical role in the
synergistic interactions between these two neurotransmitter sig-
naling cascades within the hippocampus and prefrontal cortex
through activity of MAPK1 and MAPK3 (ERK1/2) (Sarantis
et al., 2009).
PKA signaling is also critical for maturation of prefrontal
cortex D1 excitability in adolescence, a region well-known for
alterations in schizophrenia and a time period of particular vul-
nerability (Heng et al., 2011). Inhibition of phosphodiesterase
4 (PDE4), an enzyme implicated in schizophrenia and involved
in the auto-inhibition of PKA signaling, increases D1 signal-
ing in pyramidal neurons of the prefrontal cortex and enhanced
sensory gating behavior in mice as measured by prepulse inhibi-
tion (PPI) (Juraeva et al., 2014). Interestingly, both schizophre-
nia and control subjects carrying a schizophrenia-risk associated
variant within the TCF4 gene and mice moderately overexpress-
ing TCF4, a transcription factor downstream of PKA signaling,
(Figure 2) also have disrupted PPI activity (Brzózka et al., 2010
and Quednow et al., 2014). Evidence for a role of this molecule in
schizophrenia is extensive (Quednow et al., 2014). TCF4 mRNA
expression is increased in human induced pluripotent stem cells
(hiPSC) from schizophrenia patients (Brennand et al., 2011) and
increased in postmortem DLPFC samples of miR-137 risk SNP
carriers (Guella et al., 2013).
The remaining PKA gene set molecule, PTGS2, encoding the
COX-2 protein, is gaining attention as a schizophrenia drug tar-
get because inhibitors appear to be beneficial in symptom treat-
ment (Müller et al., 2010; Baheti et al., 2013). PTGS2 mRNA
expression is altered in the prefrontal cortex of patients (Tang
et al., 2012). This risk gene is relevant to the inflammatory basis
theories for schizophrenia (Feigenson et al., 2014). As depicted in
Figure 2, PTGS2 is involved in inflammatory processes such as
infection, a potential risk factor for the disorder.
New research suggests that the standard methods for func-
tional enrichment analyses of miRNA regulated genes may be
biased and inaccurate, resulting in false positive findings. This
bias is due to a lack of multiple testing correction and a high
rate of false positives in miRNA target prediction (Bleazard et al.,
2015). To assess the validity of our pathway selection, we rean-
alyzed the pathway enrichment of our predicted and validated
miR-137 regulated genes and found that these pathways were
still significantly enriched following multiple testing correction
(corrected p < 0.01). We then limited our list of predicted miR-
137 regulated genes to only those with CLIP-Seq evidence in the
starBase v2.0 database (Yang et al., 2011; Li et al., 2014) and
again found all pathways to be significantly enriched (corrected
p < 0.05). Additionally we did a final evaluation irrespective
of TargetScan prediction of only the miR-137 regulated genes
with at least five supporting experiments in the starBase database
and, and again found that all pathways except synaptic LTP
and cardiac B-adrenergic signaling were among the most signifi-
cantly enriched following multiple testing correction (p < 0.05).
These results (Supplemental Table 3) strongly suggest that our
pathway selection was valid and that these pathways may be
especially vulnerable to alterations in miR-137 regulation. Fur-
thermore, our effort to evaluate gene sets derived from a variety
of higher-confidence target lists help verify our schizophrenia-
risk enrichment findings by reducing the inclusion of falsely pre-
dicted miR-137 targets, while still evaluating true targets that
may be eliminated by higher prediction constraints. Still, there
is the potential that our lists include a few falsely predicted target
genes and are missing some true targets not predicted by Tar-
getScan. Our inclusion of experimentally validated miR-137 reg-
ulated genes assists with this, but this list is still limited to a small
subset of targets.
Another limitation of this analysis is the lack of evaluation for
the possible creation of new binding sites from polymorphisms
in unpredicted target genes. Our current tools do not allow eval-
uation of how target SNPs might impact regulation. Given the
heterogeneity and polygenicity of schizophrenia, our replication
sample size was too small to allow full replication of many of our
results (Purcell et al., 2009). However the replication of associ-
ated variants within the validated target PKA signaling gene set
suggests that other signaling pathways gene set risk association
may be replicated in a larger sample and greatly strengthens our
findings for this particular gene set. Moreover, the use of the PGC
stage 1 dataset (Ripke et al., 2011) provided a unique opportunity
for use of a very large dataset giving confidence to our findings.
Further replication with larger sample sizes will help validate our
results.
Despite these limitations, our analysis of the enrichment of
schizophrenia-associated variants within pathway specific gene
sets of potential miR-137 targets suggests that these pathways
are particularly vulnerable to dysregulation by this miRNA. Fur-
ther research to evaluate the influence of this miRNA on these
pathways in schizophrenia is therefore warranted.
Conclusions
Genetic association studies indicate that variants within miRNAs
and targets can have great impact on specific diseases (Abelson,
2005; Wang et al., 2008). These studies often evaluate variants
within one risk gene of interest at a time, and discover alterations
in miRNA binding to that specific target risk gene. However, each
miRNA has the capacity to target hundreds of targets and impact
many different pathways, so determining possible variants associ-
ated with disease that impact miRNA regulation, can be challeng-
ing. Thus studies like this, evaluatingmany putative and validated
targets, are necessary first steps to guide further research on the
impact of specific miRNAs in diseases.
Many schizophrenia relevant pathways were previously iden-
tified to have an overrepresentation of miR-137 target genes.
Our findings of schizophrenia-associated variants within PKA
signaling and other pathways provide a map to guide further
investigation of the role of this miRNA in this illness.
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FIGURE 2 | miR-137 targets within Protein Kinase A (PKA) Signaling Pathway. This figure depicts the canonical PKA signaling pathway according to Ingenuity
Pathway Analysis. Predicted miR-137 targets based on TargetScan are indicated in pink and experimentally validated regulated genes are indicated in dark blue.
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